The Oncology Institute Appoints Two New Board Members

Rhea-AI Summary

The Oncology Institute, Inc. (NASDAQ: TOI) announced the addition of Mark Pacala and Gabe Ling to its Board of Directors, expanding the board to nine members. This strategic move aims to strengthen the company as it grows in the oncology sector, leveraging their deep healthcare management and investment expertise. Pacala brings over 30 years of experience in healthcare, including leadership roles at major companies, while Ling co-founded M33 Growth, focusing on emerging technology and healthcare investments. Their insights are expected to guide TOI's pursuit of its strategic objectives.

Positive

• Board expansion aims to enhance strategic guidance.
• Mark Pacala and Gabe Ling bring extensive healthcare and investment experience.

Negative

• None.

Expands board to 9 members with deep healthcare management and investment experience

CERRITOS, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today announced the appointment of Mark Pacala and Gabe Ling to serve on its Board of Directors (“Board”), effective immediately.

“We are very pleased to have Mark and Gabe join our Board of Directors,” said Brad Hively, Chief Executive Officer of TOI. “As TOI continues to expand and mature as a public company, we are excited to attract new talent to our board. Mark and Gabe bring significant industry experience and we look forward to benefitting from their insights and guidance as we continue to pursue our strategic objectives and strive to be the nation’s leading value-based oncology group.”

“TOI is an innovator in the industry and I look forward to partnering with Brad and the entire board as the company grows and expands its unique value proposition in new markets,” said Mr. Pacala.

Mr. Pacala brings more than 30 years of general management and private equity experience in healthcare and consumer services companies. Mr. Pacala is a senior advisor for several private equity firms and serves on the board of several portfolio companies in the healthcare industry. Earlier in his career, he held leadership roles at Marriott Corporation and Walt Disney Company. Mr. Pacala was also CEO of Forum Group and American Whole Health. He was a general partner at Essex Woodlands Health Venture until 2009 and senior advisor at Oak Hill Capital Partners until 2016, focusing on healthcare investments. Mr. Pacala holds a Bachelor of Arts from Hamilton College and a Master of Business Administration from Harvard Business School.

“I am very excited about the road ahead for TOI and I look forward to engaging with management and the board to help identify and maximize growth opportunities for the company,” said Mr. Ling.

Mr. Ling is the Co-Founder of M33 Growth, a Boston-based venture capital and growth equity firm that invests in emerging technology and healthcare companies and partners with founders to rapidly grow their businesses. Mr. Ling has led investments in companies including The Oncology Institute, Acclivity Health, Dependable Health Services, YAPI, and RHI Group. Before starting M33 Growth, he was a Partner at General Catalyst, a leading venture capital firm where he spent over a decade helping entrepreneurs build their companies. While at General Catalyst, he served on several boards including Datalogix (acquired by Oracle), CLEAResult (acquired by General Atlantic), Oceans Healthcare (acquired by Webster Capital), OGSystems (acquired by Parsons), and Brighter (acquired by Cigna). Mr. Ling holds a Bachelor of Arts from Yale University.

About The Oncology Institute, Inc.

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Media Contact
Julie Korinke
JulieKorinke@theoncologyinstitute.com
(562) 735-3226 x 88806

Juan Lezama
juanlezama@theoncologyinstitute.com
(562) 374-8434

Investor Relations
Solebury Trout
Maria Lycouris
investors@theoncologyinstitute.com

FAQ

What is the significance of the new board members for The Oncology Institute (TOI)?

The addition of Mark Pacala and Gabe Ling to TOI's Board of Directors is intended to enhance strategic guidance as the company pursues growth and expansion in the oncology sector.

Who are the new board members appointed to The Oncology Institute?

Mark Pacala and Gabe Ling have been appointed to TOI's Board of Directors, bringing significant experience in healthcare management and investment.

When did the new board members start their roles at TOI?

Mark Pacala and Gabe Ling joined the Board of Directors of The Oncology Institute effective immediately as of September 22, 2022.

What experience does Mark Pacala bring to The Oncology Institute?

Mark Pacala has over 30 years of general management and private equity experience in healthcare, previously holding leadership roles at major companies.

What is Gabe Ling's professional background?

Gabe Ling is the Co-Founder of M33 Growth and has extensive experience in venture capital, with a focus on healthcare investments.